ACOR - アコ―ダ・セラピュ―ティクス （Acorda Therapeutics Inc.） アコ―ダ・セラピュ―ティクスACORのチャート
ACORの企業情報
| symbol | ACOR |
|---|---|
| 会社名 | Acorda Therapeutics Inc （アコ―ダ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アコーダ・セラピューティクス（Acorda Therapeutics Inc.）はバイオ医薬品会社である。同社は神経障害患者を治療する療法の開発に従事する。同社は多発性硬化症（MS）患者の歩行を改善するための10ミリグラム（mg）のAmpyra（dalfampridine）延長放出錠剤を含む3件の米国食品医薬品局（FDA）承認治療薬を販売する。同社はまたZanaflexカプセルとタブレット、痙縮の管理のための短時間作用型の薬であるアメリカ食品医薬品局(FDA)認可薬及び帯状疱疹後神経痛関連の神経障害性疼痛の管理向けのFDA認可皮膚パッチであるQutenzaを販売する。同社はパーキンソン病、偏頭痛、多発性硬化症（MS）等の各種疾患を治療する神経療法のパイプラインを有する。同社の製品候補はレボドパの自己投与吸入用治療製剤であるCVT-301である。 アコ―ダ・セラピュ―ティクスは、米国のバイオ医薬品販売会社。多発性硬化症や脊髄損傷、および神経系の他の疾患の神経機能を改善する新しい治療法の開発および商業化を行う。また、チザニジン塩酸塩を含む｢ザナフレックス｣錠を販売する。本社は、ニューヨーク州ア―ズリ―。 Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. |
| 本社所在地 | 420 Saw Mill River Road Ardsley NY 10502 USA |
| 代表者氏名 | Ron Cohen ロン・コーエン |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 914-347-4300 |
| 設立年月日 | 34759 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2006年 |
| 従業員数 | 484人 |
| url | www.acorda.com |
| nasdaq_url | https://www.nasdaq.com/symbol/acor |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 167.04000 |
| 終値（lastsale） | 17.65 |
| 時価総額（marketcap） | 838089299.45 |
| 時価総額 | 時価総額（百万ドル） 776.83520 |
| 売上高 | 売上高（百万ドル） 588.93000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 724.12520 |
| 当期純利益 | 当期純利益（百万ドル） -145.06100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Acorda Therapeutics Inc revenues increased less than 1% to $259.5M. Net income totaled $38M vs. loss of $27.1M. Revenues reflect Net product revenues increase of 3% to $253.4M also reflect License revenue decrease from $6.7M to $0K Royalty revenues decrease of 11% to $6.1M. Net income reflects Research and development - decrease of 40% to $54.8M (expense). |
ACORのテクニカル分析
ACORのニュース
Results from Acorda Therapeutics Inc. (ACOR) show potential 2023/02/20 17:40:00 US Post News
A share of Acorda Therapeutics Inc. (NASDAQ:ACOR) closed at $0.91 per share on Friday, up from $0.91 day before. While Acorda Therapeutics Inc. has overperformed by 0.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACOR fell by -57.74%, with highs and lows ranging from $2.29 […]
Acorda Therapeutics Granted Nasdaq Extension to Meet Minimum Bid Price 2023/02/14 21:52:02 Investing.com
https://www.investing.com/news/assorted/acorda-therapeutics-granted-nasdaq-extension-to-meet-minimum-bid-price-432SI-3003394
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement 2023/02/14 21:46:00 Acorda Therapeutics
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Nasdaq Hearings Panel has granted the Company’s extension request until June 20, 2023 to regain compliance with the Nasdaq''s minimum $1 bid price per share requirement. “We are pleased Nasdaq has granted us this extension,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. “We have announced a detailed business plan and long-term financial guidance to demonstrate what we believe is a path to growing shareholder value in Acorda. The key components of that plan are continued fiscal discipline, growing the Inbrija trajectory, and maintaining the Ampyra brand. We believe that it is in the best interests of our shareholders that we achieve compliance with the bid price rule organically by executing on that plan.” If at any time before June 20, 2023 the bid price of Acorda’s stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the
Hot Stock’s Highlights: Acorda Therapeutics, Inc. (NASDAQ:ACOR 0.84%), Nabriva Therapeutics plc (NASDAQ:NBRV 1.63%) 2023/02/04 13:47:31 Stock Equity
Acorda Therapeutics, Inc. (NASDAQ:ACOR) with the stream of 0.84% also noticed, India Nabriva Therapeutics plc (NASDAQ:NBRV) encountered a rapid change of 1.63% in the last hour of Friday’s trading session. … The post Hot Stock’s Highlights: Acorda Therapeutics, Inc. (NASDAQ:ACOR 0.84%), Nabriva Therapeutics plc (NASDAQ:NBRV 1.63%) appeared first on Stocks Equity .
Acorda Therapeutics Inc. (NASDAQ: ACOR) Shares Are Set To Rise By 2023 2023/01/21 14:00:00 Stocks Register
Acorda Therapeutics Inc. (NASDAQ:ACOR) shares, rose in value on Friday, 01/20/23, with the stock price down by -0.51% to the previous day’s close as strong demand from buyers drove the stock to $0.98. Actively observing the price movement in the last trading, the stock closed the session at $0.98, falling within a range of $0.916 … Acorda Therapeutics Inc. (NASDAQ: ACOR) Shares Are Set To Rise By 2023 Read More »
Acorda Edges up on Making Interest Payment 2022/12/05 14:54:00 Baystreet Canada
Acorda Therapeutics, Inc. (NASDAQ: ACOR) saw its shares make small gains Monday, on word today that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture. According to Monday morning’s news release, Acorda may elect to make interest payments under the Indenture in cash or shares of the Company’s common stock. The Company made the interest payment using cash that was placed in escrow when the Notes were issued, which is reported on the Company’s balance sheet as restricted cash. By making this interest payment in cash, the Company has ensured that there was no dilution to shareholders. The company was in the news in November on approving a stock split. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks.
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders 2022/11/11 14:52:00 Business Wire
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
How Is The Market Feeling About Acorda Therapeutics? 2022/11/09 20:06:09 Benzinga
Acorda Therapeutics''s (NASDAQ: ACOR ) short percent of float has risen 230.3% since its last report. The company recently reported that it has 792 thousand shares sold short , which is 3.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.3 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Can you still get a good price for Acorda Therapeutics Inc. (ACOR) Shares at this point? 2022/11/07 14:32:00 US Post News
As of Friday, Acorda Therapeutics Inc.’s (NASDAQ:ACOR) stock closed at $0.78, down from $0.80 the previous day. While Acorda Therapeutics Inc. has underperformed by -2.59%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACOR fell by -80.50%, with highs and lows ranging from $4.20 to $0.26, […]
Analysts Provide Insight On How High Acorda Therapeutics Inc. (ACOR) Can Go 2022/11/04 11:00:00 Stocks Register
Acorda Therapeutics Inc. (NASDAQ:ACOR) concluded the trading at $0.80 on Thursday, November 03 with a rise of 10.94% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.72 and 5Y monthly beta was reading 0.52 with its price kept floating in the … Analysts Provide Insight On How High Acorda Therapeutics Inc. (ACOR) Can Go Read More »
Acorda Edges up on Making Interest Payment 2022/12/05 14:54:00 Baystreet Canada
Acorda Therapeutics, Inc. (NASDAQ: ACOR) saw its shares make small gains Monday, on word today that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture. According to Monday morning’s news release, Acorda may elect to make interest payments under the Indenture in cash or shares of the Company’s common stock. The Company made the interest payment using cash that was placed in escrow when the Notes were issued, which is reported on the Company’s balance sheet as restricted cash. By making this interest payment in cash, the Company has ensured that there was no dilution to shareholders. The company was in the news in November on approving a stock split. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks.
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders 2022/11/11 14:52:00 Business Wire
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
How Is The Market Feeling About Acorda Therapeutics? 2022/11/09 20:06:09 Benzinga
Acorda Therapeutics''s (NASDAQ: ACOR ) short percent of float has risen 230.3% since its last report. The company recently reported that it has 792 thousand shares sold short , which is 3.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.3 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Can you still get a good price for Acorda Therapeutics Inc. (ACOR) Shares at this point? 2022/11/07 14:32:00 US Post News
As of Friday, Acorda Therapeutics Inc.’s (NASDAQ:ACOR) stock closed at $0.78, down from $0.80 the previous day. While Acorda Therapeutics Inc. has underperformed by -2.59%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACOR fell by -80.50%, with highs and lows ranging from $4.20 to $0.26, […]
Analysts Provide Insight On How High Acorda Therapeutics Inc. (ACOR) Can Go 2022/11/04 11:00:00 Stocks Register
Acorda Therapeutics Inc. (NASDAQ:ACOR) concluded the trading at $0.80 on Thursday, November 03 with a rise of 10.94% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.72 and 5Y monthly beta was reading 0.52 with its price kept floating in the … Analysts Provide Insight On How High Acorda Therapeutics Inc. (ACOR) Can Go Read More »